… This question cannot be addressed in this meta-analysis of gefitinib and erlotinib as most of
… relative PFS benefit, OS did not statistically significantly differ between gefitinib or erlotinib vs …

… Iressa Survival Evaluation in Lung Cancer (ISEL) study, gefitinib failed to show a survival
benefit … Conversely, erlotinib demonstrated a survival benefit for recurrent advanced NSCLC in …

… statistically significant survival benefit for erlotinib therapy as … gefitinib as second-line or
subsequent therapy; however, a statistically significant survival benefit was not found for gefitinib …

… afatinib followed by osimertinib could have survival benefit for patients with EGFR mutated
… by osimertinib in terms of survival benefit over gefitinib or erlotinib, which was not reported in …

… Eight large-scale, randomized, phase III trials were conducted to evaluate the survival benefits
of gefitinib or erlotinib (Tarceva; OSI Pharmaceuticals Inc, Melville, NY), another EGFR-TKI…

… with adjuvant cisplatin chemotherapy has no survival benefit. … of a clinical trial of perioperative
gefitinib. The surgical database … erlotinib or gefitinib delivery, disease status, and survival. …

… The PFS benefit was consistent in all subgroups including stage, sex, ethnicity, performance
… had more pronounced PFS benefit. Overall survival benefit was observed in patients with …

… inhibitor (EGFR TKI) erlotinib is an established option for … Treatment with erlotinib produces
significant survival benefits … These benefits are particularly important, given that survival …

… A systematic review of lung cancer patients’ preferences found that even small survival
benefits are sufficient to justify chemotherapy for advanced or metastatic NSCLC, 6 but patients’ …

… Preplanned sub-group analyses showed significantly longer survival in the gefitinib group
… Among patients of Asian origin, treatment with gefitinib showed a survival advantage than …